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Melasma is a common hypermelanotic disorder aﬀecting the facial area which has a considerable psychological impact on the
patient. Managing melasma is a diﬃcult challenge that requires long-term treatment with a number of topical agents, such as
rucinol and sophora-alpha. Aims. We aim to compare the combined treatment of skin needling and depigmenting serum with that
using depigmenting serum alone in the treatment of melasma, in order to evaluate the use of microneedles as a means to enhance
the drug’s transdermal penetration. Methods. Twenty patients were treated with combined skin needling and depigmenting serum
on one side of the face and with depigmenting serum alone on the other side. The outcome was evaluated periodically for up to
two months using the Melasma Area Severity Index score and the Spectrocolorimeter X-Rite 968. Results. The side with combined
treatment (skin needling + depigmenting serum) presented a statistically signiﬁcant reduction in MASI score and luminosity
index (L) levels compared to the side treated with depigmenting serum alone, and clinical symptoms were signiﬁcantly improved.
Conclusions. Our study suggests the potential use of combining skin needling with rucinol and sophora-alpha compounds to
achieve better results in melasma treatment compared to rucinol and sophora-alpha alone.
1.Introduction
Melasma is an extremely common disorder in women
between 20 and 45 years of age which involves alterations
in normal skin pigmentation, resulting from the hyper-
a c t i v i t yo fe p i d e r m a lm e l a n o c y t e s .I ti se x a c e r b a t e db y
sun exposure, pregnancy, oral contraceptives, and certain
antiepilepsy drugs. The women most likely to develop
melasma are those of fertile age with intermediate skin
phototypes. Three histological pigmentation patterns have
beenidentiﬁed:epidermal,inwhichthepigmentisdeposited
in the basal or suprabasal layer; dermal, with melanin-laden
macrophages in the superﬁcial and middermis; and mixed,
which is characterized by features of both the epidermal,
and the dermal patterns. Hypermelanosis may be epider-
mal (brown), dermal (blue-gray), or mixed (brown-gray).
Wood’s lamp examination distinguishes epidermal from
dermal hyperpigmentation in all skin phototypes except for
V and VI, in which it is of no use. In skin phototypes I–
IV, epidermal melasma is accentuated but dermal melasma
is not. Clinically, the condition is characterized by irregularly
shaped, asymptomatic spots ranging in color from beige to
brown,whichusuallyoccurinthemostphoto-exposedareas:
the upper lip, the cheeks, the cheekbones and the forehead.
Its pathogenesis is not yet fully understood, but there is an
association with genetic and hormonal factors, use of drugs
and cosmetics, endocrinopathies, and sun exposure [1, 2].
The management of melasma is a challenge. Con-
ventional melasma treatment includes elimination of any
possible pathogenetic factors and the use of a sunscreen
and hypopigmenting agent, often in combination with other
therapies, such as tretinoin, topical corticosteroids, or super-
ﬁcial peeling agents. These treatments do not necessarily
cure the cause of melasma, and the eﬀectiveness of each
will vary from patient to patient. Even after treatment,
skin discoloration may not always disappear completely, and2 Plastic Surgery International
each patient may have to try various treatment options to
achieve a satisfactory result. Some treatments may have to be
performed continually in order to maintain results, such as
regular application of a skin lightening agent combined with
an eﬀe c t i v eu s eo fs u n s c r e e na n da v o i d a n c eo fs u ne x p o s u r e .
Several lightening agents are available today, but hydro-
quinone, retinoic acid, and azelaic acid are the ones most
frequently used. Combination therapies, for example, with
hydroquinone, tretinoin, and corticosteroids, have also been
used in the treatment of melasma and are thought to
have greater eﬃcacy than single therapies. Other inves-
tigations have been carried out on depigmenting agents’
ability to block hypopigmentation or inhibit melanin syn-
thesis through mechanisms involving tyrosinase synthesis
inhibitors, tyrosinase activity inhibitors, cytotoxic agents for
melanocytes, inhibitors of the transfer of melanosomes to
keratinocytes, and so forth. New depigmenting products
currently being used in cosmetics are rucinol and sophora-
alpha. Rucinol inhibits the catalytic activity of tyrosinase
and is also able to act on TRP-1 (tyrosinase-related protein
1) [3]; sophora-alpha, another lightening agent, acts on the
outsideofthemelanocytebyblockingtheextracellularaction
of alpha-MSH [4–6] (responsible for activating the melanin
synthesis pathway by blocking MSH receptors).
Er:YAG laser resurfacing, dermabrasion, and combined
ultra-pulse CO2 laser with Q-switched alexandrite laser have
been reported to show beneﬁts for refractory melasma.
However, these methods are more invasive, and posttreat-
ment wound care is necessary. In addition, prolonged
erythema,hyperpigmentation,hypopigmentation,infection,
and hypertrophic scarring are potential side eﬀects. Conse-
quently,despitethesemeasures,treatmentofthisrecalcitrant
disorder is often diﬃcult and frustrating for the patient and
the clinician.
In order to achieve better results in the treatment of
melasma, in the last few years it has been proposed that
the topical application of skin lightening agents should
be combined with procedures to enhance the drugs’ skin
penetration, such as electroporation [7, 8], sonophoresis
[9, 10], and iontophoresis [11, 12]. Recently, skin needling
has been described as a new technique able to increase
transdermal drug absorption [13–20].
The purpose of our study is to compare combined
skin needling and depigmenting serum (containing two
principal topical agents: rucinol and sophora-alpha) with
depigmenting serum alone in the treatment of melasma
in order evaluate the use of skin needling as a means to
enhance the transdermal penetration of a serum containing
rucinol and sophora-alpha in managing abnormal skin
hyperpigmentation.
2.MaterialsandMethods
2.1. Patients. Twenty female patients aﬀected with melasma,
involving both hemifaces, were recruited between September
2009 and October 2009. The patients were 32–60 years old
(the average age was 53) and had Fitzpatrick skin types
III–V, as shown in detail in Table 1. All patients signed
Table 1
No. of patients (%)
Age (years)
32–40 2 (10)
41–50 8 (40)
51–60 10 (50)
Fitzpatrick skin type
III 6 (30)
IV 9 (45)
V 5 (25)
the informed consent. The ethical committee approved the
study (R.S. 36/09). Inclusion criteria were as follows: age
between 32 and 60 years, bilateral and symmetrical idio-
pathic melasma, voluntary participation, ability to compre-
hend and provide informed consent, resistance to previous
common therapies, preceding therapies discontinued at least
12 months before the start of the study, agreement not
to use other therapies during the study. Exclusion criteria
were as follows: history of keloid scarring, diabetes, bleeding
disorder, collagen vascular disease, corticosteroid therapy,
anticoagulant therapy, retionoid therapy, hormone therapy,
presence of skin cancers, warts, solar keratoses, or any skin
infection, current participation in another clinical study, any
depigmenting treatment within the past 12 months, and lack
of cooperation. Female volunteers were excluded if they were
pregnant.
2.2. Procedure. During the ﬁrst session (T0), each patient
underwent a careful dermatologic examination: an experi-
enced dermatologist clinically evaluated melasma areas on
both hemifaces by using a Wood’s lamp and the validated
scoring method Melasma Area and Severity Index (MASI)
[21]. The face of each patient was divided into four areas:
forehead, right malar region, left malar region, and chin,
corresponding to 30%, 30%, 30%, and 10% of the total face,
respectively. The severity of the melasma in each of these
four regions was assessed on the basis of three variables:
percentage of the total area involved (A), darkness (D), and
homogeneity (H). A numerical value was assigned for the
corresponding percentage area involved: 0: no involvement;
1: <10% involvement; 2: 10–29% involvement; 3: 30–49%
involvement; 4: 50–69% involvement; 5: 70–89% involve-
ment;6:90–100%involvement.Thedarknessofthemelasma
(D) compared to normal skin and the homogeneity of the
hyperpigmentation (H) were rated on a scale of 0 to 4 (0:
normal skin color with no evidence of hyperpigmentation;
1:barelyvisiblehyperpigmentation/specksofinvolvement;2:
mild hyperpigmentation/small patchy areas of involvement
<1.5cm diameter; 3: moderate hyperpigmentation/patches
of involvement >2cm diameter; 4: severe hyperpigmenta-
tion/uniform skin involvement without any clear areas). To
calculate the MASI score, the sum of the severity grade
for darkness (D) and homogeneity (H) was multiplied by
the numerical value of the areas (A) involved and by the
percentages of the four facial areas (10–30%). These valuesPlastic Surgery International 3
Figure 1: Digital standard photograph of a 44-year-old patient
aﬀe c t e dw i t hm e l a s m a .
Figure 2: Digital UV photograph of a 44-year-old patient aﬀected
with melasma.
were summated to obtain the total MASI score: forehead 0.3
(D+H)A + right malar 0.3 (D+H)A + left malar 0.3 (D+H)A
+ Chin 0.1 (D+H)A.
In order to carry out a comparative analysis, digital
photographs were collected for each patient and gathered
in a database: two right hemi-face and two left hemi-
face photographs were captured by using both standard
light and UV light; ultraviolet reﬂectance photography is
a valuable tool to accentuate pigmentation (Figures 1 and
2), but patients must wash and degrease the face before
photography to prevent reﬂection from the skin surface,
which obscures pigmentation assessment. A colorimetric
evaluation of melasma areas (right hemi-face, left hemi-face)
was performed using X-Rite (Figure 3; Spectrocolorimeter
X-rite 968). Colorimetric evaluation can objectively detect
changesinthedegreeofskinpigmentationasthecolorimeter
records color in a designated three-dimensional space: L∗,
a∗,b ∗. The ﬁrst value, luminance (L∗), expresses the
brightness of the variations in color from total black to total
white. The value a∗ is a tone of color ranging from red
(+) to green (−). When the rash appears on the skin, the
value becomes positive. The third value represented by b∗
is a tone of colour ranging from blue (−) to yellow (+). If
hyperpigmentation appears, the value becomes positive.
Figure 3: Spectrocolorimeter X-rite 968.
Figure 4: Dermaroller CIT 8: professional device.
The ﬁrst treatment, performed by a diﬀerent dermatol-
ogist, was preceded by the disinfection and the application
of a topical anaesthetic for 60 minutes on melasma right
hemifacial areas. A topical anaesthetic was also applied on
melasma left hemi-facial areas for the same time period, so
as not to introduce bias, as the PH of the topical anaesthetic
should act as a factor against or favouring the penetration of
thedepigmentingagentsused.Thiswascarriedoutbyrolling
a special device over melasma areas, (Figure 4; Dermaroller-
Model CIT 8) which consists of a 12cm plastic handle
attached to a cylinder, like a small paintroller, 20mm in
diameter and 20mm in length. The surface of the cylinder
houses24circulararraysof8needleseach(total192needles),
with a needle length of 0.5mm and a diameter of 0.02mm.
Needles and disks are ﬁrmly bound together with a special
medically approved adhesive. The tool was rolled in diﬀerent
directions: horizontally, vertically and diagonally, and right
and left. This ensured an even pricking pattern, resulting
in about 250–300pricks/cm2. As expected, the skin bled
for a short time after treatment. When bleeding stopped,
as e r o u so o z ef o r m e da n dw a sr e m o v e df r o mt h es u r f a c e
of the skin using sterile saline solution. After rolling, the
depigmentingserumwasappliedonthetreatedareas.Onthe
melasma left hemi-facial areas, depigmenting serum alone4 Plastic Surgery International
Figure 5: Dermaroller C8: home device.
was applied. This treatment was repeated twice with a one-
month interval.
In order to achieve better results, at the end of the ﬁrst
treatment, each patient was informed how to use the home
roller device (Dermaroller-Model C8; Figure 5) and apply
a depigmenting serum on melasma right hemi-facial areas.
Model C8 consists of 196 needles arranged in 8 rows whose
length is only 0.13±0.02mm, with the result that they blunt
later than those in the device for medical use only so that
the C8 model can be used at least 15 times without losing
its skin penetration capacity. Use of C8 does not require
local anaesthesia and does not cause bleeding. Patients
performed this treatment every day for two months, rolling
the home device horizontally, vertically and diagonally, and
right and left, 8 times in each direction and immediately
after applying a standardized amount of the depigmenting
serum. The authors could approximately assess the patients’
appropriate use of the device and the serum during this time
by evaluating the time needed to blunt the microneedles and
ﬁnishtheserum.Furthermore,werecommendedapplication
of a total sunscreen on both hemi-faces.
Each patient was examined one month after the ﬁrst
treatment: the same experienced dermatologist evaluated
each patient’s melasma areas on both hemi-faces, scoring
them using the same scale as previously reported, to assess
any clinical improvement in the severity of the lesions.
Digital photographs and colorimetric evaluation of melasma
areas were also collected and gathered in the database. The
last followup visit was conducted in a similar manner two
months after the ﬁrst treatment. At this point, the patients’
MASI score, digital photographs and colorimetric data were
compared with the relative data collected during the ﬁrst
treatment.
3. Results
All patient completed the study. The results achieved after
two sessions of treatment were assessed. After each treatment
Figure 6: UV digital photograph of 42-year-old woman at baseline.
Figure 7: UV digital photograph of a 42-year-old woman treated
by using skin needling with depigmenting serum (two months after
the baseline).
session, the facial skin treated using skin needling in
combination with depigmenting serum appeared reddened
and swollen, but patients stated that the redness and swelling
disappeared in two to three days. No sideeﬀect was reported
or found. All patients returned to work or normal activity
immediately, and no patient needed to take time oﬀ work.
The photographic comparison highlighted that, in the
areas treated with skin needling in combination with
depigmenting serum, hyperpigmentation was signiﬁcantly
reduced compared to areas treated using depigmenting
serum alone (Figures 6, 7, 8,a n d9). On the right hemi-
faces treated using the protocol therapy skin needling +
depigmenting serum, the baseline mean MASI score of 19.1
decreased to 14.4 (P<. 001) one month postoperatively
and to 9.2 (P<. 001) two months post operatively. On the
left hemi-faces treated using depigmenting serum alone, the
baselinemeanMASIscoreof20.4decreasedto17.4(P<. 05)
one month post operatively and to 13.3 two months post
operatively (P<. 05).Plastic Surgery International 5
Table 2
Depigmenting Serum + Skin needling Depigmenting serum alone
Pz. L∗ before treatment L∗ after treatment L∗ before treatment L∗ after treatment
1 51.70 59.89 54.80 59.94
2 55.82 65.49 55.36 60.88
3 58.45 68.22 56.77 64.89
4 54.27 64.17 56.67 63.74
5 48.85 59.63 53.15 59.55
6 59.78 70.92 61.18 62.18
7 55.09 66.30 53.92 60.97
8 52.10 63.70 51.20 57.66
9 56.73 69.27 58.18 65.52
10 56.34 67.18 59.48 65.02
11 51.45 62.02 54.54 60.55
12 60.15 70.38 59.76 66.61
13 52.60 63.70 54.39 60.03
14 56.25 64.22 56.10 59.00
15 55.91 66.10 56.83 62.03
16 50.26 65.35 55.92 59.62
17 52.73 59.73 52.13 60.79
18 50.35 64.71 51.17 59.22
19 52.72 62.71 54.73 62.14
20 55.31 65.73 52.04 61.98
Average 54.34 64.97 55.42 61.61
D STD 3.2665 3.1710 2.8177 2.425
Figure 8: UV digital photograph of 42-year old woman at baseline.
These results were conﬁrmed by a statistically signiﬁcant
increase in the average luminance value (L∗) in patients
treated with skin needling and depigmenting serum (64.97)
versus patients treated with depigmenting serum alone
(61.61; paired Student’s t-test; P<. 05). Comparing lumi-
nance values (L∗) before and after treatment, improvement
translates into an increase in brightness of 17.4% in patients
treated with skin needling and depigmenting serum; patients
treated with depigmenting serum alone showed an increase
in brightness of 11.2%, but it was less evident than the
increase in brightness of the side treated with skin needling
+ depigmenting serum.
Figure 9:UVdigitalphotographofa42-year-oldwomantreatedby
using depigmenting serum alone (two months after the baseline).
These results, shown in detail in Table 2, suggest that
the use of skin needling improves the absorption of depig-
menting serum and oﬀers an important contribution in the
treatment of melasma, which often constitutes a diﬃcult
challenge for dermatologists.6 Plastic Surgery International
4. Discussion
Despite the existence of several depigmenting agents, the
treatment of melasma is long and complicated, mainly
because it is diﬃcult for these substances to penetrate the
skin. Indeed, the stratum corneum (SC), the outermost layer
of the skin, is the main obstacle to the drugs’ percutaneous
absorption because its barrier function signiﬁcantly restricts
the drugs’ transdermal delivery [22, 23]. It ranges from 10
to 20µm in thickness and consists of highly diﬀerentiated
keratinocytes (corneocytes) embedded in an intercellular
lipid matrix of mainly fatty acids, ceramides, cholesterol, and
cholesterolsulfate.Topenetrateintotheskin,drugmolecules
mustbesmallinsizeand/orlowmolecularweight.Lipophilic
molecules can penetrate the skin deeper than hydrophilic
ones. In the last few years, the transdermal delivery of active
substanceshasbecomeanimportanttherapyusedintreating
a large number of skin diseases.
Skin penetration enhancement can be achieved either
physicallyorchemically[24–27].Manytechniqueshavebeen
developed to improve transdermal drug delivery, such as
electroporation [7, 8], sonophoresis [9, 10], and iontophore-
sis [11, 12], which are able to improve the stratum corneum
layer permeability and to enhance penetration of topical
agents through the skin.
Recently, the use of skin needling has been proposed
as a new physical strategy to increase transdermal drug
delivery. Since, 1995 this technique has been used to achieve
percutaneous collagen induction in order to reduce skin
imperfections [28, 29]. To date, skin needling has mostly
been proposed as an eﬀective method of treating scars
and wrinkles [30, 31], and it is carried out by rolling a
special device over the skin comprising a rolling barrel ﬁtted
with a variable number of microneedles. The micro-needles
penetrate through the epidermis but do not remove it; the
epidermis is only punctured and heals rapidly. The needles
seem to separate the cells from one another rather than cut
through them, and thus many cells are spared. Because the
needles are set in a roller, every needle initially penetrates at
an angle and then goes deeper as the roller turns. Finally, the
needle is extracted at a converse angle, therefore curving the
tracts and reﬂecting the path of the needle as it rolls into and
then out of the skin for about 0.5mm into the dermis. The
epidermis, and particularly the stratum corneum, remains
intact except for the minute holes, which are about four cells
in diameter [32]. In 1998, Henry et al., in the ﬁrst study on
microneedle use for transdermal drug delivery, showed an
increase in magnitude of four levels in the permeability of
human skin after the insertion of an array of 150µml o n g ,
solid silicon, out-of-plane microneedles [33]. More recently,
several authors have shown that microneedle-injected sites
have a signiﬁcantly higher transdermal penetration [13–
20]. Recent reports have tried to identify the mechanisms
involved in the enhancement of transdermal drug delivery
and several hypotheses have been proposed, though none is
completely exhaustive.
To understand the mechanism by which microneedles
increase skin permeability, McAllister et al. theoretically
modeled transdermal transport as diﬀusion through holes
of known geometry made by insertion of microneedles. All
the scientiﬁc data is based on a repetitive rolling (10 to 15
times) on the same area of the skin. In this case around 240
microinﬁltration pores per square centimeter are set and all
of these pores close within minutes [32].
It may be that the microneedles aid in bypassing the
stratum corneum and enhancing drug delivery through the
skinbyincreasingskinbloodperfusionalso.ALaserDoppler
Perfusion Monitor was used to record maximum blood ﬂow
and the time needed to reach maximum blood ﬂow in the
treatment areas. Sections treated with microneedles showed
a higher maximum blood ﬂow and reached maximum blood
ﬂow faster than sites not treated with microneedles [19].
5. Conclusions
This pilot study describes the ﬁrst report of improvement in
melasma through the use of skin needling in combination
with a depigmenting serum, and shows that combination
therapy with skin needling and topical depigmenting serum
is more eﬀective than topical depigmenting serum alone in
improvingmelasma.Asthiswasapilotstudy,wehaveneither
a large sample size nor a long-term followup; a larger sample
and longer followups are needed to assess the long-term
eﬃcacy of our results. Potential reﬁnement of the number of
sessions and treatment parameters call for further evaluation
in order to maximize the therapeutic eﬃcacy of this new
way of treating melasma, but it opens new perspectives for
employment of this device to enhance the penetration of
depigmenting compounds and to reduce treatment times.
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